2024
Using Panel Management to Identify Adult Patients With High-Risk Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis Fibrosis in a Primary Care Clinic: A Pilot Study.
Householder S, Loza A, Gupta V, Doolittle B. Using Panel Management to Identify Adult Patients With High-Risk Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis Fibrosis in a Primary Care Clinic: A Pilot Study. The Permanente Journal 2024, 1-10. PMID: 39444281, DOI: 10.7812/tpp/24.094.Peer-Reviewed Original ResearchPrimary care clinicsYears of ageCare clinicsPanel managementShear wave elastographyFIB-4 scoreElectronic health recordsDetection of patientsClinically relevant morbidityFollow-up appointmentsWave elastographyPrimary careRelevant morbidityFIB-4Advanced fibrosisFibrosis-4Adult patientsHealth recordsSubspecialty careMedical complexityExperience complicationsPatient acceptanceTargeted interventionsWork-upClinical carePredictors of Response to Venetoclax and Therapeutic Potential of CDK7 Inhibition in Multiple Myeloma
Dutta R, Thibaud S, Leshchenko V, Ram M, Melnekoff D, Bhalla S, Restrepo P, Gupta V, Barwick B, Newman S, McCafferty J, Hantash F, Nooka A, Cho H, Richard S, Rodriguez C, Rossi A, Sanchez L, Chari A, Boise L, Jagannath S, Richter J, Parekh S, Laganà A. Predictors of Response to Venetoclax and Therapeutic Potential of CDK7 Inhibition in Multiple Myeloma. 2024, 100049. DOI: 10.1016/j.bneo.2024.100049.Peer-Reviewed Original ResearchCyclin-dependent kinase 7Progression-free survivalMultiple myelomaAnalysis of RNA-seq dataMM cellsTherapeutic strategiesPatients treated with venetoclaxCDK7 inhibitor THZ1Overcome venetoclax resistanceRNA-seq dataSix-gene signaturePredictors of responseChromosome 1q gainPersonalized therapeutic strategiesDevelopment of personalized therapeutic strategiesInduce cell deathMarkers of sensitivityBCL2 inhibitorsCDK7 inhibitionMCL1 genePrognostic importanceStratify patientsCyclin-dependentMCL1 levelsPatient populationNSO-06 Protocol for Outpatient Administration of Multiple Myeloma Bispecific Antibodies Step-Up Dosing
Scott S, Roberts D, Gupta V, Joseph N, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. NSO-06 Protocol for Outpatient Administration of Multiple Myeloma Bispecific Antibodies Step-Up Dosing. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s282. DOI: 10.1016/s2152-2650(24)02331-0.Peer-Reviewed Original ResearchOA-51 Efficacy of Dara-RVD Induction Therapy in Newly Diagnosed Myeloma (NDMM) Patients ≥65 Years of Age
Joseph N, Kaufman J, Gupta V, Hofmeister C, Dhodapkar M, Scott S, Dicamillo S, Roberts D, Lonial S, Nooka A. OA-51 Efficacy of Dara-RVD Induction Therapy in Newly Diagnosed Myeloma (NDMM) Patients ≥65 Years of Age. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s32. DOI: 10.1016/s2152-2650(24)01892-5.Peer-Reviewed Original ResearchP-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients
Joseph N, Pruitt R, Gupta V, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Kaufman J. P-342 Impact of AchievingDOI: 10.1016/s2152-2650(24)02244-4. Peer-Reviewed Original ResearchP-179 Rates of Successful Diagnostic Clonal Identification (ID) With Adaptive clonoSEQ®
Morffi R, Pruitt R, Nguyen K, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Kaufman J, Nooka A. P-179 Rates of Successful Diagnostic Clonal Identification (ID) With Adaptive clonoSEQ®. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s141-s142. DOI: 10.1016/s2152-2650(24)02082-2.Peer-Reviewed Original ResearchP-234 Autocrine IL6 Signaling in Stromal Cells in Multiple Myeloma Influences the Bone Marrow Microenvironment
Matulis S, Barwick B, Bombin S, Ackley J, Gupta V, Hill G, Green D, Riddell S, Lonial S, Dhodapkar M, Boise L. P-234 Autocrine IL6 Signaling in Stromal Cells in Multiple Myeloma Influences the Bone Marrow Microenvironment. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s173. DOI: 10.1016/s2152-2650(24)02137-2.Peer-Reviewed Original ResearchStem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience
Varga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaLevine Cancer InstituteStem cell yieldNewly diagnosed multiple myeloma patientsStem cell collectionStem cell mobilizationInduction therapyG-CSFDose of G-CSFTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCell collectionCancer InstituteCD34+ cells/kgMRD-negative statusMedian patient ageStem cell harvestWinship Cancer InstituteCD34+ cellsGrowth colony-stimulating factorColony-stimulating factorNDMM patientsGoal dosePatient ageModulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injury
Singh S, Budiman T, Redmond D, Gupta V. Modulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injury. Hepatology Communications 2024, 8: e0368. PMID: 38251878, PMCID: PMC10805418, DOI: 10.1097/hc9.0000000000000368.Peer-Reviewed Original ResearchConceptsT-box transcription factorTranscription factorsMesenchymal gene expressionSignaling effectorsGene expressionGli transcription factorsGene transcription programUpregulation of TBX2Gain of functionSingle-cell sequencingExtrahepatic bile ductCellular identityTranscriptome analysisTranscriptional programsReceptor-ligand analysisMyofibroblast transdifferentiationIn vivo approachesB-cateninT-boxSignaling pathwayBile ductTbx3 expressionTbx3Primary sclerosing cholangitisBile duct ligation
2023
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Scott S, Marin E, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal 2023, 13: 191. PMID: 38114481, PMCID: PMC10730907, DOI: 10.1038/s41408-023-00963-y.Peer-Reviewed Original ResearchStatin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors
Juarez D, Buono R, Matulis S, Gupta V, Duong M, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh S, Dong V, Roberts A, Leverson J, Jalaluddin M, Liu Z, Bueno O, Boise L, Fruman D. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors. Cancer Research Communications 2023, 3: 2497-2509. PMID: 37956312, PMCID: PMC10704957, DOI: 10.1158/2767-9764.crc-23-0350.Peer-Reviewed Original ResearchProphylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration
Marin E, Scott S, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration. Blood 2023, 142: 2008. DOI: 10.1182/blood-2023-189878.Peer-Reviewed Original ResearchCytokine release syndromeGrade 3 cytokine release syndromeSeverity of CRSB-cell maturation antigenProphylactic cohortRelease syndromeMedian durationRRMM patientsAdditional patientsREMS programT-cell engaging therapiesGrade 1Institutional guidelinesDose of steroidsFirst full doseDays of dischargeEmory University HospitalCD38 monoclonal antibodyUsage of steroidsCellular Therapy criteriaDose delaysNeurotoxicity syndromeOutpatient administrationT cell surfaceTocilizumab groupA Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study
Nooka A, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Burton B, Ahmed H, Linton D, Cortoos A, Lin T, Labotka R, Noga S, Kaufman J, Lonial S. A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study. Blood 2023, 142: 4764. DOI: 10.1182/blood-2023-190871.Peer-Reviewed Original ResearchProgression-free survivalArm BPeripheral neuropathyInduction therapyPrimary endpointOverall survivalAutologous stem cell transplantGrade 3/4 peripheral neuropathyRandomized phase 2 studyTransplant-eligible myeloma patientsRandomized phase II studySecondary primary malignanciesTransplant-eligible patientsTransplant-ineligible patientsAdverse event profilePhase 2 studyPhase II studyStem cell transplantWinship Cancer InstituteInhibitor combination therapyStem cell collectionRegular clinical practiceHigh response rateMultiple myeloma studyMedian followComparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristicsEfficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma
Kaufman J, Joseph N, Gupta V, Dicamillo S, Roberts D, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Boise L. Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma. Blood 2023, 142: 4699. DOI: 10.1182/blood-2023-181783.Peer-Reviewed Original ResearchStandard-risk patientsVGPR ratesRisk patientsPart of inductionInduction therapyMyeloma patientsNDMM patientsInternational Myeloma Working Group Uniform Response CriteriaStage 3 patientsCombination of lenalidomideHigh-risk patientsPhase 3 studyCohort of patientsUniform response criteriaDistinct clinical presentationsFree light chainsInstitutional review boardLenalidomide maintenanceMedian OSMedian PFSRVD inductionLast followClinical characteristicsOverall survivalPatient characteristicsMachine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears
Lewis J, Shebelut C, Attieh M, Horwath M, Khanna A, Al-Rusan O, Ponnatt T, Smith G, Gutman D, Gupta V, Aljudi A, Cooper L, Jaye D. Machine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears. Blood 2023, 142: 7158. DOI: 10.1182/blood-2023-190686.Peer-Reviewed Original ResearchPlasma cell neoplasmsMolecular genetic subtypesBone marrow aspirate smearsMarrow aspirate smearsCell neoplasmsPlasma cellsAspirate smearsMultiple myelomaGenetic subtypesRisk stratificationBone marrow biopsy samplesCurrent prognostic systemsRisk stratification toolCommon hematologic malignancyPlasma cell morphologyMultiple myeloma casesSpecific morphologic featuresSubset of casesRecurrent genetic abnormalitiesLow-resource settingsBiologic subtypeStratification toolAggressive diseaseScanned whole slide imagesHematologic malignanciesHeterogeneous murine peribiliary glands orchestrate compartmentalized epithelial renewal
Singh S, Lian Q, Budiman T, Taketo M, Simons B, Gupta V. Heterogeneous murine peribiliary glands orchestrate compartmentalized epithelial renewal. Developmental Cell 2023, 58: 2732-2745.e5. PMID: 37909044, PMCID: PMC10842076, DOI: 10.1016/j.devcel.2023.10.004.Peer-Reviewed Original Research
2021
Cell and Tissue Therapy for the Treatment of Chronic Liver Disease
Bram Y, Nguyen DT, Gupta V, Park J, Richardson C, Chandar V, Schwartz RE. Cell and Tissue Therapy for the Treatment of Chronic Liver Disease. Annual Review Of Biomedical Engineering 2021, 23: 1-30. PMID: 33974812, PMCID: PMC8864721, DOI: 10.1146/annurev-bioeng-112619-044026.Peer-Reviewed Original ResearchConceptsLiver diseaseLiver transplantationOrgan transplantationNonalcoholic fatty liver diseaseTissue-based therapiesChronic liver diseaseFatty liver diseaseSolid organ transplantationCommon solid organ transplantationImportant clinical problemCause of deathLiver failureRisk factorsClinical problemAvailable organsTransplantationTherapyDiseaseGold standardRegenerative therapyTissue therapyTreatmentCellsSteatohepatitisMorbidity
2020
A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids
Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffré F, Zhang T, Kim TW, Harschnitz O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen DT, Cioffi M, Chandar V, Hoagland DA, Huang Y, Xiang J, Wang H, Lyden D, Borczuk A, Chen HJ, Studer L, Pan FC, Ho DD, tenOever BR, Evans T, Schwartz RE, Chen S. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell 2020, 27: 125-136.e7. PMID: 32579880, PMCID: PMC7303620, DOI: 10.1016/j.stem.2020.06.015.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionHuman disease-relevant cellsSARS-CoV-2 tropismCOVID-19 pathophysiologyExpression of chemokinesRecent clinical studiesHuman pancreatic beta cellsCOVID-19SARS-CoV-2Pancreatic beta cellsLiver organoidsPancreatic endocrine cellsRespiratory failureDopaminergic neuronsClinical studiesPrimary human isletsVirus infectionAutopsy samplesBeta cellsHuman isletsEndocrine cellsOrgan systemsInfectionCholangiocyte organoidsDisease-relevant cellsHedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells
Gupta V, Gupta I, Park J, Bram Y, Schwartz RE. Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells. Gastroenterology 2020, 159: 624-638.e9. PMID: 32289375, PMCID: PMC8204800, DOI: 10.1053/j.gastro.2020.03.075.Peer-Reviewed Original ResearchConceptsCholestatic injuryStellate cellsLiver tissueStromal cellsLiver diseaseBile ductBiliary treePortal tractsMesenchymal cellsPrimary sclerosing cholangitisAlcoholic liver diseaseEpithelial cellsMyofibroblast phenotypeQuantitative reverse transcription polymerase chain reactionBile duct ligationReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionCanals of HeringControl liver tissueHedgehog signalingSclerosing cholangitisHepatic injuryHepatocellular injuryNonalcoholic steatohepatitisPortal fibroblasts